Filtered By:
Drug: Methotrexate

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 117 results found since Jan 2013.

Methotrexate-induced toxic leukoencephalopathy: an uncommon stroke mimic
Source: Neurological Sciences - January 13, 2019 Category: Neurology Source Type: research

Cardiovascular comorbidities in rheumatoid arthritis.
Abstract Approximately 80% of patients with rheumatoid arthritis (RA) suffer from comorbidities including more than 50% from cardiovascular (CV) diseases. Inflammatory activity is the main factor connecting RA with atherosclerosis, coronary heart disease, stroke, thromboembolic events and heart failure. Altogether these affect RA patients twice as frequently as the general population and CV events are the major cause of death in RA. Besides inflammatory activity, which can be reduced or eliminated by optimal treatment and controlling the RA activity, traditional CV risk factors also contribute to the total CV ris...
Source: Zeitschrift fur Rheumatologie - January 17, 2019 Category: Rheumatology Authors: Krüger K, Nüßlein H Tags: Z Rheumatol Source Type: research

Water Extract of Acori Graminei Rhizoma Attenuates Features of Rheumatoid Arthritis in DBA/1 Mice.
Authors: Nho JH, Kim AH, Jung HK, Lee MJ, Jang JH, Yang BD, Lee HJ, Lee KH, Woo KW, Cho HW Abstract The dry rhizome of Acorus gramineus Solander, known as Acori Graminei Rhizoma, is used to treat dementia, stroke, eczema, and indigestion in traditional Chinese medicine, traditional Korean medicine, and traditional Japanese Kampo medicine. Previous studies have reported that Acori Graminei Rhizoma extract ameliorated cognitive impairment in Aβ1-42 injected mice. However, the effect of Acori Graminei Rhizoma on type II collagen induced arthritis (CIA) has not been elucidated. Thus, we evaluated the water extract of ...
Source: Evidence-based Complementary and Alternative Medicine - February 6, 2019 Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research

Plant-Derived Alkaloids: The Promising Disease-Modifying Agents for Inflammatory Bowel Disease
Conclusion This paper summarizes the current findings regarding the anti-colitis activity of plant-derived alkaloids and shows how these alkaloids exhibit significant and beneficial effects in alleviating colonic inflammation. These natural alkaloids are not only promising agents for IBD treatment but are also components for developing new wonder drugs. However, the underlying molecular mechanisms or toxicological evaluation of most plant-derived alkaloids still require much scientific research, and their actual efficacies for IBD patients have not been verified well in field research. Thus, further clinical trials to elu...
Source: Frontiers in Pharmacology - April 11, 2019 Category: Drugs & Pharmacology Source Type: research

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
This study is active but not recruiting and is registered with ClinicalTrials.gov, number NCT02706951.FindingsPatients were screened between Feb 23, 2016, and May 19, 2017 and 648 were randomly assigned to treatment. 598 (92%) completed week 14. At week 14, an ACR20 response was achieved by 89 (41%) of 216 patients (95% CI 35–48) in the continued methotrexate group, 147 (68%) of 217 patients (62–74) receiving upadacitinib 15 mg, and 153 (71%) of 215 patients (65–77) receiving upadacitinib 30 mg (p<0·0001 for both doses vs continued methotrexate). DAS28(CRP) 3·2 or lower was met by 42 (19%) of 216 (95% CI 14–2...
Source: The Lancet - May 24, 2019 Category: General Medicine Source Type: research

Physiological and pathophysiological significance of vitamin B9. Summary on the occasion of the 30-year introduction of folic acid as a dietary supplement.
Abstract Vitamin B9, also known as folate, can be found in natural and synthetic forms, mostly in vegetables or folic acid containing food supplements. By participating in the proper cell development and division, its presence is indispensable for certain basic metabolic processes. The decreased folate level of the body, mainly caused by environmental and hereditary factors as well as aging, can lead to genetic, epigenetic and metabolic changes. It can be related to the development of megaloblastic anemia, various cardiovascular diseases (such as atherosclerosis, stroke) obstetrical complications (such as abruptio...
Source: Orvosi Hetilap - June 30, 2019 Category: General Medicine Authors: Zsigrai S, Kalmár A, Valcz G, Szigeti KA, Barták BK, Nagy ZB, Igaz P, Tulassay Z, Molnár B Tags: Orv Hetil Source Type: research

Targeting Inflammation and Immune System in Acute Myocardial Infarction.
Authors: Alwi I Abstract Over more than two decades, the concept of atherosclerosis has developed and lead to inflammatory hypothesis. Inflammation plays an important role on pathogenesis of atherothrombosis and coronary heart disease (CHD), including acute coronary syndrome (ACS). Although the management of ACS has been demonstrated to be beneficial for secondary prevention of coronary heart disease (such as using statin and aspirin) and also seemed to have positive effect on inflammation, the identification of effective management, specifically targeting inflammation, has been not been comprehensively understood....
Source: Acta medica Indonesiana - February 13, 2020 Category: Internal Medicine Tags: Acta Med Indones Source Type: research

The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis.
CONCLUSION: Abatacept and TNFi were associated with decreased risk of CVD compared to csDMARDs. Minimizing glucocorticoid use and optimizing MTX dose may improve CV outcomes in patients with RA. PMID: 32801134 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - August 18, 2020 Category: Rheumatology Tags: J Rheumatol Source Type: research

Prevalence of leukoencephalopathy and its potential cognitive sequelae in cancer patients.
In conclusion, leukoencephalopathy is well-documented for ALL patients (with a focus on methotrexate), but there is a lack of knowledge for other intravenous chemotherapeutics, other oncological populations, wider age ranges and possible risk factors (e.g. history of CNS event). Furthermore, the long-term neuropsychological impact and potential risk for neurodegenerative processes due to leukoencephalopathy remains inconclusive. Hence, large international databanks, epidemiological and prospective case-control studies are necessary to stratify risk groups for CNS-related side effects. PMID: 32799637 [PubMed - as supplied by publisher]
Source: Journal of Chemotherapy - August 19, 2020 Category: Cancer & Oncology Tags: J Chemother Source Type: research

Targeting Inflammation to Reduce Residual Cardiovascular Risk
AbstractPurpose of ReviewPatients with established cardiovascular disease are at high risk for recurrent myocardial infarction, stroke, and cardiovascular death. The termresidual risk refers to this risk that persists, even after optimal treatment. Considerable progress has been made to understand the biological basis of residual risk and to devise therapies that can safely and effectively reduce risk. The presence of ongoing subclinical vascular inflammation is known to be a marker of elevated residual risk, and reductions in measures of vascular inflammation predict improved outcome in these patients.Recent FindingsRecen...
Source: Current Atherosclerosis Reports - September 2, 2020 Category: Cardiology Source Type: research

Severe, Fatal Methotrexate-related Neurotoxicity in 2 Adolescent Patients With ALL
Neurotoxicity is a well-documented adverse effect of methotrexate in the treatment of pediatric cancers. The spectrum of symptoms is broad, can include stroke-like episodes and seizures, and classically resolves within days. The majority of patients tolerate subsequent doses without recurrence of symptoms. The population of patients who experience persistent and irreversible neurologic symptoms is poorly described, with the existing literature suggestive of a relationship with radiation therapy. The authors present a case series of 2 patients with pre-B-cell acute lymphoblastic leukemia who developed severe and ultimately ...
Source: Journal of Pediatric Hematology Oncology - October 23, 2020 Category: Hematology Tags: Online Articles: Clinical and Laboratory Observations Source Type: research

Management of Primary Central Nervous System Lymphoma Using  Intra-Arterial Chemotherapy With Osmotic Blood-Brain Barrier Disruption: Retrospective Analysis of the Sherbrooke Cohort
ConclusionCIAC using HD-MTX-based protocols with OBBBD is a safe and well-tolerated procedure for the management of PCNSL. Our data suggests better PFS and survival outcomes compared to IV protocols with less hematologic toxicity and good tolerability, especially in the elderly.
Source: Frontiers in Oncology - January 20, 2021 Category: Cancer & Oncology Source Type: research

Methotrexate can prevent cardiovascular events in patients with rheumatoid arthritis: An updated meta-analysis
Conclusion: MTX can prevent CVEs in RA patients, but there is not sufficient evidence for using MTX to treat patients with CHD.
Source: Medicine - February 19, 2021 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research

P211  Aortitis: clinical experience within a tertiary centre
Conclusion Systemic inflammatory response syndrome was the commonest presenting feature. Those without GCA-like symptoms received a delayed diagnosis, which increases the risk of preventable vascular events. CT-PET remained the main diagnostic tool. Prednisolone treatment was prolonged with burdensome side- effects. Methotrexate remained the DMARD of choice, but leflunomide also showed good results. Vascular complications are common and need attention.Disclosure R.S. Andev: None.N. Ahmad: None.R. Luqmani: None.S. Dubey: None.
Source: Rheumatology - April 26, 2021 Category: Rheumatology Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news